Severe and malignant hypertension are common in primary atypical hemolytic uremic syndrome-Reference-Cited by-同舟云学术

Severe and malignant hypertension are common in primary atypical hemolytic uremic syndrome

Published:2019-10 Issue:4 Volume:96 Page:995-1004
ISSN:0085-2538
Container-title:Kidney International
language:en
Short-container-title:Kidney International

Author:

Cavero Teresa,Arjona Emilia,Soto Karina,Caravaca-Fontán Fernando,Rabasco Cristina,Bravo Luis,de la Cerda Francisco,Martín Nadia,Blasco Miquel,Ávila Ana,Huerta Ana,Cabello Virginia,Jarque Ana,Alcázar Concepción,Fulladosa Xavier,Carbayo Javier,Anaya Sara,Cobelo Carmen,Ramos Natalia,Iglesias Elena,Baltar José,Martínez-Gallardo Rocío,Pérez Lourdes,Morales Enrique,González Roberto,Macía Manuel,Draibe Juliana,Pallardó Luis,Quintana Luis F.,Espinosa Mario,Barros Xoana,Pereira Fernando,Cao Mercedes,Moreno Juan Antonio,Rodríguez de Córdoba Santiago,Praga Manuel

Publisher

Elsevier BV

Subject

Nephrology

Reference35 articles.

1. Haemolytic uraemic syndrome;Fakhouri;Lancet,2017

2. Atypical aHUS: state of the art;Nester;Mol Immunol,2015

3. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a «Kidney Disease: Improving Global Outcomes» (KDIGO) controversies conference;Goodship;Kidney Int,2017

4. Atypical hemolytic uremic syndrome;Kavanagh;Curr Opin Hematol,2010

5. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document;Campistol;Nefrologia,2015

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Kidney Outcomes Following Angiotensin Receptor-Neprilysin Inhibitor vs Angiotensin-Converting Enzyme Inhibitor/Angiotensin Receptor Blocker Therapy for Thrombotic Microangiopathy;JAMA Network Open;2024-09-12

2. Complement system activation: bridging physiology, pathophysiology, and therapy;Intensive Care Medicine;2024-09-10

3. Hot Spot of Complement Factor I Rare Variant p.Ile357Met in Patients With Hemolytic Uremic Syndrome;American Journal of Kidney Diseases;2024-08

4. Urinary complement factor D is increased in primary malignant hypertension: a single-center, cross-sectional study;Scientific Reports;2024-07-15

5. Clinical characteristics and genetic profile of complement system in renal thrombotic microangiopathy in patients with severe forms of arterial hypertension;Terapevticheskii arkhiv;2024-07-07